AI Terminal
DIACEUTICS PLC
Report Publication Announcement • Sep 7, 2023
7596_rns_2023-09-07_1126acc6-1818-4e10-be94-e9481ca72762.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 4650L
Diaceutics PLC
07 September 2023
Diaceutics to attend 10th Annual HealthTech Investment Forum in Basel on September 19
Belfast and London, 7 September 2023 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, announces that management will attend and present at the 10th Annual HealthTech Investment Forum in Basel, Switzerland on 19 September, 2023. Diaceutics CEO Peter Keeling will be a speaker at the Revolution in Precision Medicine Panel: Investing in Big Data & AI.
For more information, please click here.
Enquiries:
| Diaceutics PLC | Tel: +44 (0)28 9040 6500 |
| Peter Keeling, Chief Executive Officer Ryan Keeling, Chief Innovation Officer Nick Roberts, Chief Financial Officer |
[email protected] |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison | |
| Nick Harland Kate Hanshaw |
|
| Alma PR | Tel: +44 (0)20 3405 0205 |
| Caroline Forde | [email protected] |
| Matthew Young | |
| Kinvara Verdon |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialization solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostic Network®.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAFLFFEALIEIIV